News
In a recent study, CBD was shown to suppress localized T-cell function and activity. This suggests that the cannabinoid may be the only scientifically-backed drug prove to to be capable of treating the underlying cause of RA.
The efficacy and safety of CBD to reduce pain and inflammation in the treatment of patients with persistent symptoms of RA and AS is beginning to gain traction in the medical community as controlled studies are consistently producing promising results.
Recent research highlights the potential of non-psychoactive cannabinoids—CBD, CBG, and CBN—as promising therapeutic tools for Autism Spectrum Disorder (ASD). CBD has shown efficacy in reducing anxiety, aggression, and sleep disturbances, while CBG may support cognitive function and reduce neuroinflammation. CBN, often associated with sleep improvement, is also being studied for its neurogenic properties. The most significant benefits appear when these compounds work together in full-spectrum formulations, leveraging the entourage effect to enhance symptom relief. While further large-scale studies are needed, these findings suggest that cannabinoids could play a transformative role in ASD treatment.
